Table 2.

Comparisons of viral responses among four antiviral agents in treatment-naïve patients with chronic hepatitis B

	Lamivudine		Adefovir dipivoxil		Entecavir		Telbivudine
	e(+)	e(−)	e(+)	e(−)	e(+)	e(−)	e(+)	e(−)
HBV-DNA (-log)
Year 1	5.4a	4.5b	3.6	3.7	6.9a	5.0b	5.7c	4.4c
	5.4c	4.1c	[1.0]	[1.4]
Undetectable
Year 1	36%a	72%b	21%	61%	67%a	90%b	60%c	88%c
	40%c	71%c	[0%]	[0%]
Year 2	39%*d	NA	NA	71%	80%*d	NA	56%c	82%c
	39%c	57%c
Year 3	20%	40%	NA	77%**	89%*	NA	NA	NA
HBeAg seroconversion
Year 1	18%a	NA	12%	NA	21%a	NA	23%c	NA
	22%c		[6%]
Year 2	26%*	NA	29%	NA	31%*	NA	30%e	NA
	25%e
Year 3	40%	NA	NA	NA	NA	NA	NA	NA
Genotypic resistance
Year 1	13%a	6%b	0%	0%*	0%a	0%b	5%c	2%c
	11%c	11%c
Year 2	38%d	31%	NA	3%*	0%d	NA	25%e	11%e
	40%e	26%e
Year 3	57%	57%	NA	11%*	∼1%	NA	NA	NA

^a–eData from same randomized controlled trials (a: [86]; b: [87]; c: [90]; d: [88]; e: [64])

Abbreviations: *, cumulative incidence; [·], data of untreated controls; **, HBV-DNA < 1,000 copies/ml

HBV: hepatitis B virus; e: hepatitis B e antigen; NA: not available